Alessio Cortellini

List of Publications by Year
in descending order

159 papers	4,048 citations	159525 30 h-index	189801 50 g-index
164 all docs	164 docs citations	164 times ranked	5236 citing authors

#	Article	IF	Citations
1	COVID-19 in patients with thoracic malignancies (TERAVOLT): first results of an international, registry-based, cohort study. Lancet Oncology, The, 2020, 21, 914-922.	5.1	503
2	A multicenter study of body mass index in cancer patients treated with anti-PD-1/PD-L1 immune checkpoint inhibitors: when overweight becomes favorable. , 2019, 7, 57.		275
3	Association of Obesity With Survival Outcomes in Patients With Cancer. JAMA Network Open, 2021, 4, e213520.	2.8	197
4	Clinical Outcomes of Patients with Advanced Cancer and Pre-Existing Autoimmune Diseases Treated with Anti-Programmed Death-1 Immunotherapy: A Real-World Transverse Study. Oncologist, 2019, 24, e327-e337.	1.9	131
5	Integrated analysis of concomitant medications and oncological outcomes from PD-1/PD-L1 checkpoint inhibitors in clinical practice. , 2020, 8, e001361.		126
6	Correlations Between the Immune-related Adverse Events Spectrum and Efficacy of Anti-PD1 Immunotherapy in NSCLC Patients. Clinical Lung Cancer, 2019, 20, 237-247.e1.	1.1	118
7	Preliminary evidence of safety and tolerability of atezolizumab plus bevacizumab in patients with hepatocellular carcinoma and Childâ€Pugh A and B cirrhosis: A realâ€world study. Hepatology, 2022, 76, 1000-1012.	3.6	114
8	Another side of the association between body mass index (BMI) and clinical outcomes of cancer patients receiving programmed cell death protein-1 (PD-1)/ Programmed cell death-ligand 1 (PD-L1) checkpoint inhibitors: A multicentre analysis of immune-related adverse events. European Journal of Cancer, 2020, 128, 17-26.	1.3	85
9	Effect of concomitant medications with immune-modulatory properties on the outcomes of patients with advanced cancer treated with immune checkpoint inhibitors: development and validation of a novel prognostic index. European Journal of Cancer, 2021, 142, 18-28.	1.3	81
10	Differential influence of antibiotic therapy and other medications on oncological outcomes of patients with non-small cell lung cancer treated with first-line pembrolizumab versus cytotoxic chemotherapy. , 2021, 9, e002421.		80
11	Clinical Outcomes and Toxic Effects of Single-Agent Immune Checkpoint Inhibitors Among Patients Aged 80 Years or Older With Cancer. JAMA Oncology, 2021, 7, 1856.	3.4	74
12	Prevalence and impact of COVID-19 sequelae on treatment and survival of patients with cancer who recovered from SARS-CoV-2 infection: evidence from the OnCovid retrospective, multicentre registry study. Lancet Oncology, The, 2021, 22, 1669-1680.	5.1	73
13	Weighing the role of skeletal muscle mass and muscle density in cancer patients receiving PD-1/PD-L1 checkpoint inhibitors: a multicenter real-life study. Scientific Reports, 2020, 10, 1456.	1.6	64
14	Clinicopathologic correlates of first-line pembrolizumab effectiveness in patients with advanced NSCLC and a PD-L1 expression of â‰¥â€‰50%. Cancer Immunology, Immunotherapy, 2020, 69, 2209-2221.	2.0	60
15	Baseline BMI and BMI variation during first line pembrolizumab in NSCLC patients with a PD-L1 expression â‰¥ 50%: a multicenter study with external validation. , 2020, 8, e001403.		57
16	Predictive value of skeletal muscle mass for immunotherapy with nivolumab in nonâ€small cell lung cancer patients: A â€œhypothesisâ€generatorâ€•preliminary report. Thoracic Cancer, 2019, 10, 347-351.	0.8	54
17	Real world data of cemiplimab in locally advanced and metastatic cutaneous squamous cell carcinoma. European Journal of Cancer, 2021, 157, 250-258.	1.3	52
18	TERAVOLT: Thoracic Cancers International COVID-19 Collaboration. Cancer Cell, 2020, 37, 742-745.	7.7	51

#	Article	IF	Citations
19	Immune-related Adverse Events of Pembrolizumab in a Large Real-world Cohort of Patients With NSCLC With a PD-L1 ExpressionÂâ‰¥ 50% and Their Relationship With Clinical Outcomes. Clinical Lung Cancer, 2020, 21, 498-508.e2.	1.1	50
20	Time-Dependent COVID-19 Mortality in Patients With Cancer. JAMA Oncology, 2022, 8, 114.	3.4	50
21	Outcomes of the SARS-CoV-2 omicron (B.1.1.529) variant outbreak among vaccinated and unvaccinated patients with cancer in Europe: results from the retrospective, multicentre, OnCovid registry study. Lancet Oncology, The, 2022, 23, 865-875.	5.1	50
22	A systematic review on the emerging association between the occurrence of immune-related adverse events and clinical outcomes with checkpoint inhibitors in advanced cancer patients. Seminars in Oncology, 2019, 46, 362-371.	0.8	46
23	Notch pathway in small-cell lung cancer: from preclinical evidence to therapeutic challenges. Cellular Oncology (Dordrecht), 2019, 42, 261-273.	2.1	45
24	Home Care for Cancer Patients During COVID-19 Pandemic: The Double Triage Protocol. Journal of Pain and Symptom Management, 2020, 60, e5-e7.	0.6	45
25	Late immune-related adverse events in long-term responders to PD-1/PD-L1 checkpoint inhibitors: A multicentre study. European Journal of Cancer, 2020, 134, 19-28.	1.3	45
26	The Systemic Inflammatory Response Identifies Patients with Adverse Clinical Outcome from Immunotherapy in Hepatocellular Carcinoma. Cancers, 2022, 14, 186.	1.7	44
27	PRIME-HCC: phase Ib study of neoadjuvant ipilimumab and nivolumab prior to liver resection for hepatocellular carcinoma. BMC Cancer, 2021, 21, 301.	1.1	42
28	Treatment-related toxicity and improved outcome from immunotherapy in hepatocellular cancer: Evidence from an FDA pooled analysis of landmark clinical trials with validation from routine practice. European Journal of Cancer, 2021, 157, 140-152.	1.3	42
29	Singleâ€institution study of correlations between skeletal muscle mass, its density, and clinical outcomes in nonâ€small cell lung cancer patients treated with firstâ€line chemotherapy. Thoracic Cancer, 2018, 9, 1623-1630.	0.8	38
30	INfluenza Vaccine Indication During therapy with Immune checkpoint inhibitors: a transversal challenge. The INVIDIa study. Immunotherapy, 2018, 10, 1229-1239.	1.0	38
31	The Agnostic Role of Site of Metastasis in Predicting Outcomes in Cancer Patients Treated with Immunotherapy. Vaccines, 2020, 8, 203.	2.1	38
32	Determinants of enhanced vulnerability to coronavirus disease 2019 in UK patients with cancer: a European study. European Journal of Cancer, 2021, 150, 190-202.	1.3	37
33	Inflammatory indices and clinical factors in metastatic renal cell carcinoma patients treated with nivolumab: the development of a novel prognostic score (Meet-URO 15 study). Therapeutic Advances in Medical Oncology, 2021, 13, 175883592110196.	1.4	36
34	Are anti-PD1 and anti-PD-L1 alike? The non-small-cell lung cancer paradigm. Oncology Reviews, 2020, 14, 490.	0.8	36
35	The lung immuno-oncology prognostic score (LIPS-3): a prognostic classification of patients receiving first-line pembrolizumab for PD-L1 â‰¥ 50% advanced non-small-cell lung cancer. ESMO Open, 2021, 6, 100078.	2.0	35
36	Immunological insights on influenza infection and vaccination during immune checkpoint blockade in cancer patients. Immunotherapy, 2020, 12, 105-110.	1.0	33

#	Article	IF	Citations
37	Targeting KRAS in Solid Tumors: Current Challenges and Future Opportunities of Novel KRAS Inhibitors. Pharmaceutics, 2021, 13, 653.	2.0	33
38	Early Antibiotic Exposure Is Not Detrimental to Therapeutic Effect from Immunotherapy in Hepatocellular Carcinoma. Liver Cancer, 2021, 10, 583-592.	4.2	33
39	Association between immune-related adverse event timing and treatment outcomes. OncoImmunology, 2022, 11, 2017162.	2.1	33
40	Antibiotic-exposed patients with non-small-cell lung cancer preserve efficacy outcomes following first-line chemo-immunotherapy. Annals of Oncology, 2021, 32, 1391-1399.	0.6	32
41	Anti-PD1 antibodies in patients agedÂâ‰¥Â75 years with metastatic melanoma: A retrospective multicentre study. Journal of Geriatric Oncology, 2020, 11, 515-522.	0.5	31
42	Tryptophan Catabolism as Immune Mechanism of Primary Resistance to Anti-PD-1. Frontiers in Immunology, 2020, 11, 1243.	2.2	30
43	Smoking status during firstâ€line immunotherapy and chemotherapy in <scp>NSCLC</scp> patients: A caseâ€“control matched analysis from a large multicenter study. Thoracic Cancer, 2021, 12, 880-889.	0.8	30
44	â€œVessels in the Stormâ€• Searching for Prognostic and Predictive Angiogenic Factors in Colorectal Cancer. International Journal of Molecular Sciences, 2018, 19, 299.	1.8	29
45	Immunotherapy in Hepatocellular Carcinoma. Current Treatment Options in Oncology, 2021, 22, 87.	1.3	25
46	Impact of primary tumor location in patients with RAS wild-type metastatic colon cancer treated with first-line chemotherapy plus anti-EGFR or anti-VEGF monoclonal antibodies: a retrospective multicenter study. Journal of Cancer, 2019, 10, 5926-5934.	1.2	24
47	Predictive ability of a drug-based score in patients with advanced nonâ€“small-cell lung cancer receiving first-line immunotherapy. European Journal of Cancer, 2021, 150, 224-231.	1.3	24
48	The Gustave Roussy Immune (GRIm)-Score Variation Is an Early-on-Treatment Biomarker of Outcome in Advanced Non-Small Cell Lung Cancer (NSCLC) Patients Treated with First-Line Pembrolizumab. Journal of Clinical Medicine, 2021, 10, 1005.	1.0	23
49	Osimertinib beyond disease progression in T790M EGFR-positive NSCLC patients: a multicenter study of cliniciansâ€™ attitudes. Clinical and Translational Oncology, 2020, 22, 844-851.	1.2	21
50	Early fatigue in cancer patients receiving PD-1/PD-L1 checkpoint inhibitors: an insight from clinical practice. Journal of Translational Medicine, 2019, 17, 376.	1.8	20
51	Predictive biomarkers of response to immune checkpoint inhibitors in hepatocellular carcinoma. Expert Review of Molecular Diagnostics, 2022, 22, 253-264.	1.5	20
52	Evaluation of Second-Line Anti-VEGF after First-Line Anti-EGFR Based Therapy in RAS Wild-Type Metastatic Colorectal Cancer: The Multicenter â€œSLAVEâ€•Study. Cancers, 2020, 12, 1259.	1.7	19
53	Post-progression outcomes of NSCLC patients with PD-L1 expression â‰¥ 50% receiving first-line single-agent pembrolizumab in a large multicentreÂreal-world study. European Journal of Cancer, 2021, 148, 24-35.	1.3	19
54	Vaccination against SARS-CoV-2 protects from morbidity, mortalityÂand sequelae from COVID19 in patients with cancer. European Journal of Cancer, 2022, 171, 64-74.	1.3	19

#	Article	IF	Citations
55	COVID-19 pneumonia and immune-related pneumonitis: critical issues on differential diagnosis, potential interactions, and management. Expert Opinion on Biological Therapy, 2020, 20, 959-964.	1.4	18
56	PD-1 Blockade for Hepatocellular Carcinoma: Current Research and Future Prospects. Journal of Hepatocellular Carcinoma, 2021, Volume 8, 887-897.	1.8	17
57	Immune context characterization and heterogeneity in primary tumors and pulmonary metastases from renal cell carcinoma. Immunotherapy, 2019, 11, 21-35.	1.0	16
58	Impact of influenza syndrome and flu vaccine on survival of cancer patients during immunotherapy in the INVIDIa study. Immunotherapy, 2020, 12, 151-159.	1.0	16
59	Family history of cancer as surrogate predictor for immunotherapy with anti-PD1/PD-L1 agents: preliminary report of the FAMI-L1 study. Immunotherapy, 2018, 10, 643-655.	1.0	15
60	First-line carboplatin/nab-paclitaxel in advanced ovarian cancer patients, after hypersensitivity reaction to solvent-based taxanes: a single-institution experience. Clinical and Translational Oncology, 2020, 22, 158-162.	1.2	15
61	Correlation Between Immune-related Adverse Event (IRAE) Occurrence and Clinical Outcome in Patients With Metastatic Renal Cell Carcinoma (mRCC) Treated With Nivolumab: IRAENE Trial, an Italian Multi-institutional Retrospective Study. Clinical Genitourinary Cancer, 2020, 18, 477-488.	0.9	15
62	Differential prognostic effect of systemic inflammation in patients with nonâ€“small cell lung cancer treated with immunotherapy or chemotherapy: A post hoc analysis of the phase 3 <scp>OAK</scp> trial. Cancer, 2022, 128, 3067-3079.	2.0	15
63	Validation of the GRade, Age, Nodes and Tumor (GRANT) score within the Surveillance Epidemiology and End Results (SEER) database: A new tool to predict survival in surgically treated renal cell carcinoma patients. Scientific Reports, 2019, 9, 13218.	1.6	14
64	Symptomatic COVID-19 in advanced-cancer patients treated with immune-checkpoint inhibitors: prospective analysis from a multicentre observational trial by FICOG. Therapeutic Advances in Medical Oncology, 2020, 12, 175883592096846.	1.4	14
65	PD-1/PD-L1 checkpoint inhibitors during late stages of life: an ad-hoc analysis from a large multicenter cohort. Journal of Translational Medicine, 2021, 19, 270.	1.8	14
66	COVID-19 Sequelae and the Host Proinflammatory Response: An Analysis From the OnCovid Registry. Journal of the National Cancer Institute, 2022, 114, 979-987.	3.0	14
67	Efficacy outcomes and prognostic factors from real-world patients with advanced non-small-cell lung cancer treated with first-line chemoimmunotherapy: The Spinnaker retrospective study. International Immunopharmacology, 2022, 110, 108985.	1.7	14
68	Unlocking the secret of the obesity paradox in renal tumours. Lancet Oncology, The, 2020, 21, 194-196.	5.1	13
69	Chemotherapy in non-small cell lung cancer patients after prior immunotherapy: The multicenter retrospective CLARITY study. Lung Cancer, 2020, 150, 123-131.	0.9	13
70	Prognostic effect of body mass index in patients with advanced NSCLC treated with chemoimmunotherapy combinations. , 2022, 10, e004374.		13
71	Prognostic clinical factors in patients affected by non-small-cell lung cancer receiving Nivolumab. Expert Opinion on Biological Therapy, 2020, 20, 319-326.	1.4	12
72	Clinical Outcomes of Patients With Metastatic Urothelial Carcinoma After Progression to Immune Checkpoint Inhibitors: A Retrospective Analysis by the Meet-Uro Group (Meet-URO 1 Study). Clinical Medicine Insights: Oncology, 2021, 15, 117955492110216.	0.6	12

#	Article	IF	Citations
73	Clinical outcomes of NSCLC patients experiencing early immune-related adverse events to PD-1/PD-L1 checkpoint inhibitors leading to treatment discontinuation. Cancer Immunology, Immunotherapy, 2022, 71, 865-874.	2.0	11
74	Combined PD-1/VEGFR Blockade: A New Era of Treatment for Hepatocellular Cancer. Clinical Cancer Research, 2021, 27, 908-910.	3.2	11
75	Persistence of long-term COVID-19 sequelae in patients with cancer: An analysis from the OnCovid registry. European Journal of Cancer, 2022, 170, 10-16.	1.3	11
76	An Italian Retrospective Survey on Bone Metastasis in Melanoma: Impact of Immunotherapy and Radiotherapy on Survival. Frontiers in Oncology, 2020, 10, 1652.	1.3	10
77	The Impact of Locoregional Treatment on Response to Nivolumab in Advanced Platinum Refractory Head and Neck Cancer: The Need Trial. Vaccines, 2020, 8, 191.	2.1	10
78	Expression of pro-angiogenic factors as potential biomarkers in experimental models of colon cancer. Journal of Cancer Research and Clinical Oncology, 2020, 146, 1427-1440.	1.2	10
79	The interplay between cholesterol (and other metabolic conditions) and immune-checkpoint immunotherapy: shifting the concept from the â€œinflamed tumorâ€• to the â€œinflamed patientâ€• Human Vaccines and Immunotherapeutics, 2021, 17, 1930-1934.	1.4	10
80	The systemic pro-inflammatory response: targeting the dangerous liaison between COVID-19 and cancer. ESMO Open, 2021, 6, 100123.	2.0	10
81	Topical menthol for treatment of chemotherapy-induced peripheral neuropathy. Indian Journal of Palliative Care, 2017, 23, 350.	1.0	10
82	New Frontiers in the Medical Therapy of Hepatocellular Carcinoma. Chemotherapy, 2022, 67, 164-172.	0.8	10
83	Weight loss and body mass index in advanced gastric cancer patients treated with second-line ramucirumab: a real-life multicentre study. Journal of Cancer Research and Clinical Oncology, 2019, 145, 2365-2373.	1.2	9
84	What cancer patients actually know regarding medical cannabis? A cross-sectional survey with a critical analysis of the current attitudes. Journal of Oncology Pharmacy Practice, 2019, 25, 1439-1444.	0.5	9
85	Evaluating the role of FAMIly history of cancer and diagnosis of multiple neoplasms in cancer patients receiving PD-1/PD-L1 checkpoint inhibitors: the multicenter FAMI-L1 study. OncoImmunology, 2020, 9, 1710389.	2.1	9
86	Status of correlation between BMI and response to immunocheck-point inhibitor in advanced non-small-cell lung cancer. Lung Cancer Management, 2020, 9, LMT26.	1.5	9
87	Palliative radiotherapy in advanced cancer patients treated with immuneâ€‘checkpoint inhibitors: The PRACTICE study. Biomedical Reports, 2020, 12, 59-67.	0.9	9
88	A Definitive Prognostication System for Patients With Thoracic Malignancies Diagnosed With Coronavirus Disease 2019: An Update From the TERAVOLT Registry. Journal of Thoracic Oncology, 2022, 17, 661-674.	0.5	9
89	Antibiotic-dependent effect of probiotics in patients with non-small cell lung cancer treated with PD-1 checkpoint blockade. European Journal of Cancer, 2022, 172, 199-208.	1.3	9
90	Weekly alternate intensive regimen FIrB/FOx in metastatic colorectal cancer patients: an update from clinical practice . OncoTargets and Therapy, 2019, Volume 12, 2159-2170.	1.0	8

#	Article	IF	Citations
91	Safe Administration of anti-PD-L1 Atezolizumab in a Patient with Metastatic Urothelial Cell Carcinoma and End-Stage Renal Disease on Dialysis. Case Reports in Oncological Medicine, 2019, 2019, 1-3.	0.2	8
92	Cliniciansâ€™ Attitude to Doublet Plus Anti-EGFR Versus Triplet Plus Bevacizumab as First-line Treatment in Left-Sided RAS and BRAF Wild-Type Metastatic Colorectal Cancer Patients: A Multicenter, â€œReal-Lifeâ€, Case-Control Study. Clinical Colorectal Cancer, 2021, , .	1.0	8
93	Cancer Care After Natural Disaster: Different Countries, Similar Problems. Journal of Global Oncology, 2019, 5, 1-2.	0.5	7
94	The treatment paradigm of right-sided metastatic colon cancer: harboring BRAF mutation makes the difference. International Journal of Colorectal Disease, 2020, 35, 1513-1527.	1.0	7
95	Knowledge and attitudes of Italian medical oncologists and palliative care physicians toward medical use of cannabis in cancer care: a national survey. Supportive Care in Cancer, 2021, 29, 7845-7854.	1.0	7
96	Systemic therapy for pre-treated malignant mesothelioma: A systematic review, meta-analysis and network meta-analysis of randomised controlled trials. European Journal of Cancer, 2022, 166, 287-299.	1.3	7
97	Host immuneâ€inflammatory markers to unravel the heterogeneous outcome and assessment of patients with <scp>PDâ€L1</scp> â‰¥50% metastatic nonâ€small cell lung cancer and poor performance status receiving firstâ€line immunotherapy. Thoracic Cancer, 2022, 13, 483-488.	0.8	7
98	Novel immunotherapy combinations in clinical trials for hepatocellular carcinoma: will they shape the future treatment landscape?. Expert Opinion on Investigational Drugs, 2022, 31, 681-691.	1.9	7
99	Coronavirus Disease 2019 Outcomes, Patient Vaccination Status, and Cancer-Related Delays During the Omicron Wave: A Brief Report From the TERAVOLT Analysis. JTO Clinical and Research Reports, 2022, 3, 100335.	0.6	7
100	Multicentric retrospective analysis of platinumâ€pemetrexed regimens as firstâ€line therapy in nonâ€squamous nonâ€small cell lung cancer patients: A â€œsnapshotâ€•from clinical practice. Thoracic Cancer, 2018, 9, 241-252.	0.8	6
101	Safe Administration of Ipilimumab, Pembrolizumab, and Nivolumab in a Patient with Metastatic Melanoma, Psoriasis, and a Previous Guillainâ€“BarrÃ© Syndrome. Case Reports in Oncological Medicine, 2018, 2018, 1-4.	0.2	6
102	Clinical outcomes to pemetrexed-based versus non-pemetrexed-based platinum doublets in patients with KRAS-mutant advanced non-squamous non-small cell lung cancer. Clinical and Translational Oncology, 2020, 22, 708-716.	1.2	6
103	Supporting Clinical Decision-Making during the SARS-CoV-2 Pandemic through a Global Research Commitment: The TERAVOLT Experience. Cancer Cell, 2020, 38, 602-604.	7.7	6
104	Preliminary results from a phase Ib study of neoadjuvant ipilimumab plus nivolumab prior to liver resection for hepatocellular carcinoma: The PRIME-HCC trial.. Journal of Clinical Oncology, 2022, 40, 4093-4093.	0.8	6
105	KRAS and 2 rare PI3KCA mutations coexisting in a metastatic colorectal cancer patient with aggressive and resistant disease. Human Pathology, 2018, 74, 178-182.	1.1	5
106	The possible different roles of denosumab in prevention and cure breast cancer bone metastases: A â€˜hypothesisâ€˜generatorâ€™ study from clinical practice. Oncology Letters, 2018, 16, 7195-7203.	0.8	5
107	A Comparison Between First-, Second- and Third-Generation Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitors in Patients with Non-Small-Cell Lung Cancer and Brain Metastases. Journal of Molecular Pathology, 2021, 2, 1-10.	0.5	5
108	Post-Induction Management in Patients With Left-Sided RAS and BRAF Wild-Type Metastatic Colorectal Cancer Treated With First-Line Anti-EGFR-Based Doublet Regimens: A Multicentre Study. Frontiers in Oncology, 2021, 11, 712053.	1.3	5

#	Article	IF	Citations
109	COVID-19 in breast cancer patients: a subanalysis of the OnCovid registry. Therapeutic Advances in Medical Oncology, 2021, 13, 175883592110534.	1.4	5
110	High familial burden of cancer correlates with improved outcome from immunotherapy in patients with NSCLC independent of somatic DNA damage response gene status. Journal of Hematology and Oncology, 2022, 15, 9.	6.9	5
111	The PERSONS score for symptoms assessment in simultaneous care setting: A pilot study. Palliative and Supportive Care, 2019, 17, 82-86.	0.6	4
112	The PERSONS score: A new tool for cancer patientsâ€™ symptom assessment in simultaneous care and home care settings. Palliative and Supportive Care, 2020, 18, 33-38.	0.6	4
113	Haloperidol for the treatment of opioid addiction in advanced cancer patients: a case series. Journal of Addictive Diseases, 2020, 38, 229-234.	0.8	4
114	Antibiotic Exposure and Immune Checkpoint Inhibitors in Patients With NSCLC: The Backbone Matters. Journal of Thoracic Oncology, 2022, 17, 739-741.	0.5	4
115	Artificial intelligence in digital pathology approach identifies the predictive impact of tertiary lymphoid structures with immune-checkpoints therapy in NSCLC.. Journal of Clinical Oncology, 2022, 40, 9065-9065.	0.8	4
116	Influenza vaccine indication during anticancer therapy with immune-checkpoint inhibitors: A transversal challenge for patientâ€™s counselling â€“ preliminary analysis of the INVIDIa study. Annals of Oncology, 2017, 28, xi17.	0.6	3
117	Timedâ€‘flat infusion of 5â€‘fluorouracil with docetaxel and oxaliplatin as firstâ€‘line treatment of gastroesophageal adenocarcinoma: A single institution experience with the FD/FOx regimen. Oncology Reports, 2018, 40, 803-812.	1.2	3
118	Evaluation of Prognostic Factors for Survival in Transverse Colon Cancer. Cancers, 2020, 12, 2457.	1.7	3
119	GU-CA-COVID: a clinical audit among Italian genitourinary oncologists during the first COVID-19 outbreak. Therapeutic Advances in Urology, 2021, 13, 175628722110543.	0.9	3
120	A phase Ib study of pembrolizumab following trans-arterial chemoembolization (TACE) in hepatocellular carcinoma (HCC): PETAL.. Journal of Clinical Oncology, 2022, 40, e16195-e16195.	0.8	3
121	Anthracycline-Free Neoadjuvant Treatment in Patients with HER2-Positive Breast Cancer: Real-Life Use of Pertuzumab, Trastuzumab and Taxanes Association with an Exploratory Analysis of PIK3CA Mutational Status. Cancers, 2022, 14, 3003.	1.7	3
122	Immune Checkpoint Inhibitors and Myasthenic Syndromes: A Case Report of a Metastatic Renal Cell Carcinoma Patient Treated With Nivolumab. Journal of Clinical Neuromuscular Disease, 2018, 20, 99-100.	0.3	2
123	Looking for A Place for Dose-Dense TMZ Regimens in GBM Patients: An Experience with MGMT Exploratory Evaluation. Bioengineering, 2019, 6, 11.	1.6	2
124	Family History of Cancer as Potential Prognostic Factor in Stage III Colorectal Cancer: a Retrospective Monoinstitutional Study. Journal of Gastrointestinal Cancer, 2020, 51, 1094-1101.	0.6	2
125	Clinical determinants of complete response to vismodegib in locally advanced basal cell carcinoma: a multicentre experience. Journal of the European Academy of Dermatology and Venereology, 2021, 35, e923-e926.	1.3	2
126	A reflection on the actual place of osimertinib in the treatment algorithm of EGFR-positive non-small cell lung cancer patients. Journal of Thoracic Disease, 2020, 12, 6107-6111.	0.6	2

#	Article	IF	Citations
127	Antibiotic therapy and association with oncological outcomes from targeted and immune-based therapy in hepatocellular carcinoma (HCC).. Journal of Clinical Oncology, 2022, 40, 4089-4089.	0.8	2
128	P043 Bevacizumab/paclitaxel as first line therapy for metastatic breast cancer: new schedule in real life. Breast, 2015, 24, S41.	0.9	1
129	Timed-flat infusion (TFI) 5-fluorouracil with irinotecan and oxaliplatin in pancreatic adenocarcinomas: A single institution experience with FIr/FOx regimen. Annals of Oncology, 2018, 29, v37-v38.	0.6	1
130	Family history of cancer and DNA damage response genes: Two sides of the same coin?. Thoracic Cancer, 2019, 10, 401-401.	0.8	1
131	Rare bone toxicity associated with vismodegib. JAAD Case Reports, 2020, 6, 482-485.	0.4	1
132	Into the storms: Organising oncological home care services during natural disasters and global pandemics. European Journal of Cancer Care, 2021, 30, e13433.	0.7	1
133	Determinants of enhanced vulnerability to Covid-19 in U.K. cancer patients: Results from the OnCovid study.. Journal of Clinical Oncology, 2021, 39, 1574-1574.	0.8	1
134	Therapeutic targeting of VEGFR2 in HBV-associated hepatocellular carcinoma. The Lancet Gastroenterology and Hepatology, 2021, 6, 515-516.	3.7	1
135	Response to letter entitled: Re: Predictive ability of a drug-based score in advanced non-small cell lung cancer patients receiving first-line immunotherapy. European Journal of Cancer, 2021, 155, 315-316.	1.3	1
136	The way towards tailored treatment for metastatic renal cancer patients in the omics era: are we getting a â€œtranscriptomic compassâ€?. Annals of Translational Medicine, 2019, 7, S190-S190.	0.7	1
137	The Promising Link Among Tumor Mutational Burden, Immune-Related Adverse Events, and Immune Checkpoint Inhibitors Efficacy in SCLC. JTO Clinical and Research Reports, 2020, 1, 100080.	0.6	1
138	A reflection on the actual place of osimertinib in the treatment algorithm of EGFR-positive non-small cell lung cancer patients. Journal of Thoracic Disease, 2020, 12, 6107-6111.	0.6	1
139	A multicenter study of skin toxicity management in patients with left-sided, RAS/BRAF wild-type metastatic colorectal cancer treated with first-line anti-EGFR-based doublet regimen: is there room for improvement?. Supportive Care in Cancer, 2021, 30, 2455.	1.0	1
140	One more piece to SOLIDify our knowledge on the impact of SARS-CoV-2 in patients with cancer. Translational Lung Cancer Research, 2022, 11, 132-134.	1.3	1
141	Osimertinib as induction therapy for oligometastatic non-small cell lung cancer with EGFR mutation: a case report. Translational Lung Cancer Research, 2022, 11, 686-696.	1.3	1
142	Clinical assessment of the Omicron outbreak in Europe and trends in morbidity and mortality from COVID-19 and cancer.. Journal of Clinical Oncology, 2022, 40, e18673-e18673.	0.8	1
143	Digital quantification of lymphocytic infiltration on routine H&E images and immunotherapy response in nonâ€“small cell lung cancer.. Journal of Clinical Oncology, 2022, 40, 9066-9066.	0.8	1
144	Differential prognostic effect of systemic inflammation in patients with NSCLC treated with immunotherapy or chemotherapy: A post hoc analysis of the phase III OAK trial.. Journal of Clinical Oncology, 2022, 40, 9056-9056.	0.8	1

#	Article	IF	Citations
145	Retrospective evaluation of chemotherapy options in non-squamous non-small cell lung cancer (non-Sq NSCLC) patients (pts) unfit for standard platinum-based chemotherapy in clinical practice. Annals of Oncology, 2015, 26, vi88.	0.6	0
146	Prognostic relevance of Hormonal Receptor positive Status in HER2-positive Metastatic Breast Cancer Patients: Retrospective Analysis in Real Life. Annals of Oncology, 2015, 26, vi20.	0.6	0
147	Oncology Network ASL1 Abruzzo: first year activity bridging the gap between Hospital and Territorial Care. Annals of Oncology, 2016, 27, iv56.	0.6	0
148	Where are we with treatment options after first line in small cell lung cancer?Â°â„¢report of two opposite cases treated with CAPTEM regimen and possible perspectives. Journal of Thoracic Disease, 2018, 10, E520-E525.	0.6	0
149	Baseline predictive factors for efficacy of anti-PD1 used in first line in melanoma patients: An Italian melanoma intergroup study. Annals of Oncology, 2018, 29, viii449.	0.6	0
150	â€œPalliativeâ€•or â€œSupportiveâ€• Is It Just a Matter of Word?. Journal of Palliative Medicine, 2018, 21, 1546-1546.	0.6	0
151	A real-life multicenter study on body weight loss and body mass index in advanced Gastric Cancer patients treated with Ramucirumab-based second-line therapy. Annals of Oncology, 2019, 30, iv27.	0.6	0
152	Letter to the Editor: considerations about recent findings on long-term adverse events of PD-1/PD-L1 checkpoint inhibitors. European Journal of Cancer, 2020, 139, 41-42.	1.3	0
153	Treatment-related toxicity and improved outcomes with immune checkpoint inhibitors in patients with hepatocellular carcinoma.. Journal of Clinical Oncology, 2021, 39, 4085-4085.	0.8	0
154	Prognostic relevance of KRAS genotype and the prevalent C.35 G > a mutation in metastatic colorectal cancer (MCRC) patients fitting for intensive FIr-B/FOx triplet chemotherapy plus bevacizumab.. Journal of Clinical Oncology, 2014, 32, e14575-e14575.	0.8	0
155	First-line chemotherapy with docetaxel, oxaliplatin, and timed-flat infusion 5Fluorouracil in metastatic gastro-esophageal adenocarcinomas: The experience with FD/FOx regimen.. Journal of Clinical Oncology, 2018, 36, 178-178.	0.8	0
156	Family history of cancer as surrogate predictor for immunotherapy with anti-PD-1/PD-L1 immune checkpoint inhibitors: The FAMI-L1 study.. Journal of Clinical Oncology, 2019, 37, 2559-2559.	0.8	0
157	The prognostic role of nephrectomy in patients (pts) with metastatic renal cell carcinoma (mRCC) treated with immunotherapy according to the novel prognostic Meet-URO score: Subanalysis of the Meet-URO 15 study.. Journal of Clinical Oncology, 2022, 40, 4535-4535.	0.8	0
158	Clinical effectiveness of SARS-CoV-2 vaccines and booster doses in patients with cancer: An analysis from the European OnCovid registry.. Journal of Clinical Oncology, 2022, 40, e18725-e18725.	0.8	0
159	Comparative efficacy of novel combination immunotherapy strategies for unresectable hepatocellular carcinoma (HCC): A network metanalysis of landmark phase III trials.. Journal of Clinical Oncology, 2022, 40, 4098-4098.	0.8	0